{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:58:19Z","timestamp":1760162299861},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.cca.2024.117847","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T03:46:31Z","timestamp":1709005591000},"page":"117847","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Familial hypercholesterolemia with special focus on Japan"],"prefix":"10.1016","volume":"556","author":[{"given":"Junji","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Minamizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koutaro","family":"Yokote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2024.117847_b0005","series-title":"Familial Hypercholesterolemia. in the Metabolic and Molecular Bases of Inherited Disease","author":"Goldstein","year":"2000"},{"key":"10.1016\/j.cca.2024.117847_b0010","first-page":"322","article-title":"Relationship between pathogenesis of xanthoma and disturbance of lipid metabolism (in japanese)","volume":"6","author":"Yamakawa","year":"1922","journal-title":"Tohoku Igakuzasshi."},{"key":"10.1016\/j.cca.2024.117847_b0015","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0002-9343(78)90822-7","article-title":"Homozygous familial hypercholesterolemia in Japan","volume":"65","author":"Mabuchi","year":"1978","journal-title":"Am. J. Med."},{"key":"10.1016\/j.cca.2024.117847_b0020","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1073\/pnas.71.3.788","article-title":"Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase activity","volume":"71","author":"Brown","year":"1974","journal-title":"Proc. Natl. Acad. Sci. U S a."},{"key":"10.1016\/j.cca.2024.117847_b0025","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1172\/JCI110184","article-title":"Effects of ML-236b (compactin) on sterol synthesis and low density lipoprotein receptor activities in fibroblasts of patients with homozygous familial hypercholesterolemia","volume":"67","author":"Haba","year":"1981","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2024.117847_b0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0092-8674(84)90188-0","article-title":"The human LDL receptor: a cysteine-rich protein with multiple alu sequences in its mRNA","volume":"39","author":"Yamamoto","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.cca.2024.117847_b0035","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1469-1809.2012.00724.x","article-title":"Low density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment","volume":"76","author":"Usifo","year":"2012","journal-title":"Ann. Hum. Genet."},{"key":"10.1016\/j.cca.2024.117847_b0040","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cca.2024.117847_b0045","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.atherosclerosis.2014.06.005","article-title":"Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin\/kexin type 9 (PCSK9) gain-of-function mutation","volume":"236","author":"Mabuchi","year":"2014","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.cca.2024.117847_b0050","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2024.117847_b0055","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jacl.2020.05.007","article-title":"The first japanese cases of familial hypercholesterolemia due to a known pathogenic APOB gene variant, c.10580 G>A: p","volume":"14","author":"Hori","year":"2020","journal-title":"(Arg3527Gln). J. Clin. Lipidol."},{"key":"10.1016\/j.cca.2024.117847_b0060","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1210\/jc.2002-021487","article-title":"Clinical features and genetic analysis of autosomal recessive hypercholesterolemia","volume":"88","author":"Harada-Shiba","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cca.2024.117847_b0065","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.atherosclerosis.2011.08.004","article-title":"Novel type of familial hypercholesterolemia: double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene","volume":"219","author":"Tada","year":"2011","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.cca.2024.117847_b0070","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5551\/jat.RV16008","article-title":"Half a century Tales of familial hypercholesterolemia (FH) in Japan","volume":"24","author":"Mabuchi","year":"2017","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.cca.2024.117847_b0075","doi-asserted-by":"crossref","first-page":"665","DOI":"10.5551\/jat.RV17050","article-title":"Homozygous familial hypercholesterolemia","volume":"28","author":"Nohara","year":"2021","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.cca.2024.117847_b0080","doi-asserted-by":"crossref","unstructured":"M. Harada-Shiba, T. Ohta, A. Ohtake, M. Ogura, K. Dobashi, A. Nohara, S. Yamashita, K. Yokote & Joint Working Group by Japan Pediatric Society and Japan Atherosclerosis Society for Making Guidance of Pediatric Familial Hypercholesterolemia, Guidance for Pediatric Familial Hypercholesterolemia 2017. J. Atheroscler. Thromb. 25 (2018) 539\u2013553.","DOI":"10.5551\/jat.CR002"},{"key":"10.1016\/j.cca.2024.117847_b0085","doi-asserted-by":"crossref","first-page":"558","DOI":"10.5551\/jat.CR005","article-title":"Guidelines for the diagnosis and treatment of adult familial hypercholesterolemia 2022","volume":"30","author":"Harada-Shiba","year":"2023","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.cca.2024.117847_b0090","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5551\/jat.CR003","article-title":"Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017","volume":"25","author":"Harada-Shiba","year":"2018","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.cca.2024.117847_b0095","doi-asserted-by":"crossref","first-page":"816","DOI":"10.5551\/jat.62869","article-title":"Achilles tendon thickness assessed by X-ray predicting a pathogenic mutation in familial hypercholesterolemia gene","volume":"29","author":"Tada","year":"2022","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.cca.2024.117847_b0100","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/eurheartj\/ehx004","article-title":"Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia","volume":"38","author":"Tada","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cca.2024.117847_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.872056","article-title":"Effects of different types of pathogenic variants on phenotypes of familial hypercholesterolemia","volume":"13","author":"Tada","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.cca.2024.117847_b0110","unstructured":"T. Minamizuka, J. Kobayashi, H. Tada, M. Koshizaka, Y. Maezawa, H. Ono, K. Yokote, A Japanese case of familial hypercholesterolemia with a protein-truncating variant in LDLR and a PCSK9 variant without significant atherosclerosis but showing remarkable Achilles tendon thickening. Internal Medicine, in press."},{"key":"10.1016\/j.cca.2024.117847_b0115","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cca.2024.117847_b0120","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1476-511X-13-65","article-title":"Risk stratification of patients with familial hypercholesterolemia in a multi-ethnic cohort","volume":"13","author":"Allard","year":"2014","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.cca.2024.117847_b0125","doi-asserted-by":"crossref","first-page":"e018263","DOI":"10.1161\/JAHA.120.018263","article-title":"Patients with LDLR and PCSK9 gene variants experienced higher incidence of cardiovascular outcomes in heterozygous familial hypercholesterolemia","volume":"10","author":"Doi","year":"2021","journal-title":"J. Am. Heart. Assoc."},{"key":"10.1016\/j.cca.2024.117847_b0130","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jacl.2020.03.002","article-title":"A catalog of the pathogenic mutations of LDL receptor gene in japanese familial hypercholesterolemia","volume":"14","author":"Tada","year":"2020","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.cca.2024.117847_b0135","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.jacl.2018.08.006","article-title":"Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease","volume":"12","author":"Tada","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.cca.2024.117847_b0140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.atherosclerosis.2006.12.035","article-title":"Genetic variants in PCSK9 in the japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population","volume":"196","author":"Miyake","year":"2008","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.cca.2024.117847_b0145","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejim.2004.09.017","article-title":"Severely elevated serum triglycerides in a case of heterozygous familial hypercholesterolemia with the 317 cysteine to serine mutation in the LDL receptor gene","volume":"16","author":"Kobayashi","year":"2005","journal-title":"Eur J. Intern. Med."},{"key":"10.1016\/j.cca.2024.117847_b0150","doi-asserted-by":"crossref","unstructured":"W. Yu, A. Nohara, T. Higashikata, H. Lu, A. Inazu, H. Mabuchi, Molecular genetic analysis of familial hypercholesterolemia: spectrum and regional difference of LDL receptor gene mutations in Japanese population. Atherosclerosis.165,(2002) 335-342. Erratum in: Atherosclerosis.174 (2004) 399-400.","DOI":"10.1016\/j.atherosclerosis.2004.03.002"},{"key":"10.1016\/j.cca.2024.117847_b0155","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0140-6736(95)92627-5","article-title":"Absence of familial defective apolipoprotein B-100 in japanese patients with familial hypercholesterolaemia","volume":"345","author":"Nohara","year":"1995","journal-title":"Lancet."},{"key":"10.1016\/j.cca.2024.117847_b0160","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the european atherosclerosis society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cca.2024.117847_b0165","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1093\/eurheartj\/ehv289","article-title":"Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes","volume":"36","author":"Nanchen","year":"2015","journal-title":"Eur Heart J."},{"key":"10.1016\/j.cca.2024.117847_b0170","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0022-2275(20)41379-3","article-title":"The discovery and development of HMG-CoA reductase inhibitors","volume":"33","author":"Endo","year":"1992","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2024.117847_b0175","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0021-9150(80)90124-0","article-title":"Therapeutic effects of ML-236B in primary hypercholesterolemia","volume":"35","author":"Yamamoto","year":"1980","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.cca.2024.117847_b0180","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJM198108273050902","article-title":"Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia","volume":"305","author":"Mabuchi","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2024.117847_b0185","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1056\/NEJM198108273050909","article-title":"Lowering plasma cholesterol by raising LDL receptors","volume":"305","author":"Brown","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2024.117847_b0190","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM198303173081101","article-title":"Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. additive effects of compactin and cholestyramine","volume":"308","author":"Mabuchi","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2024.117847_b0195","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2024.117847_b0200","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2024.117847_b0205","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJMe1202168","article-title":"Lowering plasma cholesterol by raising LDL receptors\u2013revisited","volume":"366","author":"Young","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2024.117847_b0210","doi-asserted-by":"crossref","unstructured":"R.P. Giugliano T.R. Pedersen J.G. Park GMDe Ferrari GM, Z.A. Gaciong, R. Ceska, K. Toth, I. Gouni-Berthold, J. Lopez-Miranda, F. Schiele, F. Mach, B.R. Ott, E. Kanevsky, A.L. Pineda, R. Somaratne, S.M. Wasserman, A.C. Keech, P.S. Sever, M.S. Sabatine, Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial Lancet 390 2017 1962 1971.","DOI":"10.1016\/S0140-6736(17)32290-0"},{"key":"10.1016\/j.cca.2024.117847_b0215","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2024.117847_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2023.100503","article-title":"Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11","volume":"14","author":"Koenig","year":"2023","journal-title":"Am. J. Prev. Cardiol."},{"key":"10.1016\/j.cca.2024.117847_b0225","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","article-title":"Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia","volume":"129","author":"Rader","year":"2014","journal-title":"Circulation."},{"key":"10.1016\/j.cca.2024.117847_b0230","doi-asserted-by":"crossref","unstructured":"M. Cuchel E.A. Meagher H. du Toit Theron D.J. Blom A.D. Marais R.A. Hegele M.R. Averna C.R. Sirtori P. KShah, D. Gaudet, C. Stefanutti, G.B. Vigna, A.M. Du Plessis, K.J. Propert, W.J. Sasiela, L.T. Bloedon, D.J. Rader, Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study Lancet 381 2013 40 46.","DOI":"10.1016\/S0140-6736(12)61731-0"},{"key":"10.1016\/j.cca.2024.117847_b0235","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2217\/clp.13.38","article-title":"MTP inhibitor for treating severe LDL-cholesterolemia","volume":"8","author":"Mabuchi","year":"2013","journal-title":"Clin. Lipidol."},{"key":"10.1016\/j.cca.2024.117847_b0240","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2024.117847_b0245","doi-asserted-by":"crossref","unstructured":"I.K. Luirink A. Wiegman D.M. Kusters M.H. Hof J.W. Groothoff E.de Groot, J. J. P. Kastelein, B. A. Hutten, 20-year follow-up of statins in children with familial hypercholesterolemia N. Engl. J. Med. 381 2019 1547 1556.","DOI":"10.1056\/NEJMoa1816454"},{"key":"10.1016\/j.cca.2024.117847_b0250","doi-asserted-by":"crossref","first-page":"489","DOI":"10.5551\/jat.RV17040","article-title":"Low-density lipoprotein cholesterol level cannot be too low: considerations from clinical trials, human genetics, and biology","volume":"27","author":"Tada","year":"2020","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.cca.2024.117847_b0255","doi-asserted-by":"crossref","first-page":"608","DOI":"10.5551\/jat.62764","article-title":"Effectiveness and safety of lipid-lowering drug treatments in japanese patients with familial hypercholesterolemia: familial hypercholesterolemia expert forum (FAME) study","volume":"29","author":"Yamashita","year":"2022","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.cca.2024.117847_b0260","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.atherosclerosis.2023.03.005","article-title":"Attainment of the low-density lipoprotein cholesterol treatment target and prognosis of heterozygous familial hypercholesterolemia","volume":"371","author":"Tada","year":"2023","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.cca.2024.117847_b0265","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the european atherosclerosis society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cca.2024.117847_b0270","doi-asserted-by":"crossref","unstructured":"H. Tada, H. Kaneko, Y. Suzuki, A. Okada, N. Takeda, K. Fujiu, H. Morita, J. Ako, K. Node, Y. Takeji, M. Takamura, H Yasunaga, I Komuro, Familial hypercholesterolemia is related to cardiovascular disease, heart failure and atrial fibrillation. Results from a population-based study. Eur. J. Clin. Invest. e14119(2023).","DOI":"10.1111\/eci.14119"},{"key":"10.1016\/j.cca.2024.117847_b0275","doi-asserted-by":"crossref","first-page":"839","DOI":"10.5551\/jat.62780","article-title":"Universal screening for familial hypercholesterolemia in children in Kagawa, Japan","volume":"29","author":"Matsunaga","year":"2022","journal-title":"J. Atheroscler. Thromb."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124000883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124000883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T02:55:39Z","timestamp":1716087339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898124000883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":55,"alternative-id":["S0009898124000883"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2024.117847","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Familial hypercholesterolemia with special focus on Japan","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2024.117847","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117847"}}